Milestones & Awards | Lee's Pharmaceutical

Milestones

2022

Officially launched the Flagship eStore on Ali’s and JD’s Platforms in March 2022.

2021

Successfully listed on the “2020 Top 100 ranking of Chinese Chemical Pharmaceutical Companies” 

Zhaoke Ophthalmology Limited successfully listed on Main Board of the Stock Exchange of Hong Kong Limited (Stock code:6622) on 29 April 2021

2020

Successfully raised approximately US$145 million through the private placement of series B preferred shares of Zhaoke Ophthalmology Limited in October 2020

2019

Successfully raised approximately US$50 million through the private placement of series A preferred shares of China Ophthalmology Focus Limited in May 2019

Formation of Lee’s Pharmaceutical Taiwan Limited, registered and operated in Taiwan on 9 April 2019

2018

Completed the merger of CVie Therapeutics Limited with Windtree Therapeutics, Inc. in December 2018

2017

Establishment of China Ophthalmology Focus Limited

Completed the acquisition of majority of shares in Windtree Therapeutics, Inc. at a consideration of US$10 million in November 2017

Successfully carried out the reorganization of CVie Therapeutics Company Limited into two companies: CVie Therapeutics Limited for Taiwan business and CVie Therapeutics Company Limited for China business

Successfully raised approximately US$7.5 million through the private placement of series A preferred shares of CVie Therapeutics Limited in May 2017

2016

Nansha Facility obtained Manufacturing License for Tablet and Capsule on 30 June 2016

2015

Establishment of Guangzhou Zhaokang Hospital Company Limited and acquisition of the land parcel with a total site area of approximately 36,656 m² and with a total planned gross floor area of approximately 65,981m² specifically for medical and sanitary use in Nansha District, Guangzhou, China in September 2015

Formation of Zhaoke Pharmaceutical (Guangzhou) Company Limited, registered and operated in Nansha District, Guangzhou, China

Inclusion to various Hang Seng Family of Indexes

Inclusion to MSCI China Indexes

Formation of Lee’s Healthcare Industry Fund L.P. with a maximum fund size of US$20.2 million in August 2015

Successfully raised approximately HK$383 million through the placement of new shares of the Company in April 2015

2014

Formation of China Oncology Focus Limited with the management of the Company

2013

Successfully raised approximately US$10 million through the private placement of series B preferred shares of CVie Therapeutics Company Limited in August 2013

Successfully raised approximately US$3 million through the private placement of series A-2 preferred shares of CVie Therapeutics Company Limited in March 2013

2012

Successfully raised approximately US$4 million through the private placement of series A-1 preferred shares of CVie Therapeutics Company Limited in July 2012

Establishment of China Cardiovascular Focus Limited and CVie Therapeutics Company Limited

Successfully raised approximately HK$152 million through the placement of new shares of the Company to GL Trade Investment Limited in May 2012

2011

Establishment of Guangzhou Zhaoke Lian Fa Medicine Company Limited

2010

Successfully raised approximately HK$40 million through the placement of new shares of the Company to an investor in October 2010

Successfully transfer of listing from GEM to Main Board of the Stock Exchange of Hong Kong Limited (Stock code: 950) on 14 May 2010

Establishment of Powder Pharmaceuticals, Incorporated

2009

Successfully raised approximately HK$19 million through the placement of new shares of the Company to an investor in August 2009

2005

Completed the acquisition of the interests in Zhaoke Pharmaceutical (Hefei) Company Limited from the PRC partner and became a wholly owned subsidiary of the Group

2004

Successfully raised approximately HK$24 million through the placement of new shares and unlisted warrants of the Company to an investor in August 2004

2002

Lee’s Pharmaceutical Holdings Limited announced listing of Initial Public Offering of shares on the Growth Enterprise Market (“GEM”) of the Stock Exchange of Hong Kong Limited and the shares commenced trading on 15 July 2002

1994

Formation of Zhaoke Pharmaceutical (Hefei) Company Limited with a PRC partner, registered and operated in Hefei City, Anhui Province, China

Establishment of the Group in 1994